Volpara Health Technologies

About the author:

Author name:

By Scott Power

Job title:

Senior Analyst

Date posted:

02 June 2016, 12:22 PM

Sectors Covered:

Healthcare, Life Sciences

Company overview

Volpara (VHT) is a digital health company offering a solution that improves clinical decision making for early detection of breast cancer.  VHT's products are approved for sale in key regions and provide objective evidence that can be used by relevant specialists including the woman herself to make informed decisions about further screening.  

Key points

• Breast density is critical in determining appropriate and effective screening options for women.
• In many US states legislative changes are now mandating that breast density is provided to patients following a mammogram screen.
• With an estimated 75m breast screens performed globally per annum, the market opportunity is significant, in our view.

More information

Morgans clients can login to view our latest detailed report for Volpara Health Technologies (VHT). Alternatively, please contact your nearest Morgans office for access.

Disclaimer(s): Morgans was a Lead Manager to the IPO offer of shares in Volpara and received fees in this regard.

Analyst owns shares.

The information contained in this report is provided to you by Morgans Financial Limited as general advice only, and is made without consideration of an individual's relevant personal circumstances. Morgans Financial Limited ABN 49 010 669 726, its related bodies corporate, directors and officers, employees, authorised representatives and agents (“Morgans”) do not accept any liability for any loss or damage arising from or in connection with any action taken or not taken on the basis of information contained in this report, or for any errors or omissions contained within. It is recommended that any persons who wish to act upon this report consult with their Morgans investment adviser before doing so.